Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age… Read more
Emmaus Life Sciences Inc (EMMA) - Total Liabilities
Latest total liabilities as of September 2025: $80.24 Million USD
Based on the latest financial reports, Emmaus Life Sciences Inc (EMMA) has total liabilities worth $80.24 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Emmaus Life Sciences Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Emmaus Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Emmaus Life Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Emmaus Life Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coreo AG
F:CORE
|
Germany | €74.74 Million |
|
BOOZ ALLEN HAM-A
BE:BZ9
|
Germany | €5.68 Billion |
|
Hestia Insight Inc
OTCQB:HSTA
|
USA | $262.81K |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
India | ₹99.34 Million |
|
Giant Motorsports Inc
PINK:BZRD
|
USA | $131.52K |
|
Genomic Vision Société Anonyme
F:G09
|
Germany | €6.73 Million |
|
CL8 Holdings Ltd
AU:CL8
|
Australia | AU$13.01 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down Emmaus Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Emmaus Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Emmaus Life Sciences Inc (1999–2024)
The table below shows the annual total liabilities of Emmaus Life Sciences Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $80.08 Million | -3.44% |
| 2023-12-31 | $82.94 Million | +0.75% |
| 2022-12-31 | $82.32 Million | +5.28% |
| 2021-12-31 | $78.18 Million | +20.85% |
| 2020-12-31 | $64.69 Million | -8.25% |
| 2019-12-31 | $70.51 Million | +3680.04% |
| 2018-12-31 | $1.87 Million | +20.44% |
| 2017-12-31 | $1.55 Million | -1.77% |
| 2016-12-31 | $1.58 Million | -70.82% |
| 2015-12-31 | $5.40 Million | +74.44% |
| 2014-12-31 | $3.10 Million | -13.04% |
| 2013-12-31 | $3.56 Million | -73.01% |
| 2012-12-31 | $13.20 Million | +11.95% |
| 2011-12-31 | $11.79 Million | +165.47% |
| 2010-12-31 | $4.44 Million | +95.59% |
| 2009-12-31 | $2.27 Million | +43.68% |
| 2008-12-31 | $1.58 Million | +139.74% |
| 2007-12-31 | $659.30K | +100.09% |
| 2006-12-31 | $329.51K | +5.29% |
| 2005-12-31 | $312.94K | +7.05% |
| 2004-12-31 | $292.32K | +981.83% |
| 2003-12-31 | $27.02K | +59.62% |
| 2002-12-31 | $16.93K | +13.73% |
| 2001-12-31 | $14.88K | +134.63% |
| 2000-12-31 | $6.34K | -36.56% |
| 1999-12-31 | $10.00K | -- |